A plastic pill for periodontal problems

Sep 14, 2006

Rutgers scientists announced a revolutionary new treatment for killing the bacteria that attack gum tissue during periodontal disease, while also promoting healing and the regeneration of tissue and bone around the teeth.

Eight to 12 percent of Americans have periodontal disease serious enough to require some type of advanced treatment, such as surgery. Left untreated, the condition can lead to tooth loss.

The breakthrough technology – a polymer-based drug delivery system that may be implanted in pockets between the teeth and the gum – developed at Rutgers, The State University of New Jersey, was presented at the 232nd National Meeting of the American Chemical Society in San Francisco by Michelle Johnson, a graduate student in the research group of paper co-author Kathryn Uhrich, a professor of chemistry and chemical biology at Rutgers.

"There has never been anything like this available to clinicians and it will certainly find a very prominent role in periodontal therapy in the future," said Mark Reynolds, chair of the department of periodontics at the University of Maryland Dental School, who collaborates with Uhrich on the research.

The new polymer or "plastic" material, when inserted between tooth and diseased gum, treats the bacterial infection, inflammation and pain with pharmaceuticals incorporated into the material itself, Johnson explained. It employs salicylic acid, the active ingredient in aspirin, for the swelling and discomfort, and three antimicrobials each with a different release rate – compounds of clindamycin, chlorhexidrine and minocycline.

Once implanted, the polymer gradually breaks down to release the salicylic acid, which relieves pain and reduces inflammation, and the antimicrobials which inhibit infection at a sustained pace, Uhrich added.

Periodontal disease occurs when plaque that forms on the tooth surface spreads and grows below the gum line. The plaque carries with it bacteria that can irritate, inflame and eventually destroy the tissues and bone that support the teeth. Spaces or pockets form between the teeth and gums and become sites of infection which can damage the supporting structures of the teeth.

Reynolds explained that after removing the damaged tissue, periodontists often try to separate the gum tissue from the bone and tooth structure using barrier materials that remain in place for about six weeks to facilitate healing and tissue regeneration.

"The polymers that Kathryn Uhrich and her team have pioneered and developed are unique in that they can serve as barriers while also repressing any inflammatory response, setting the stage for nature to not only heal these areas, but also to regenerate the tissues that have been lost to the disease," Reynolds said.

Reynolds is testing the new biomaterial in a number of animal systems to assess tissue reactions and better define the timeline of its decomposition and drug release. He says that human clinical trials may be two or more years away depending on approvals from the U.S. Food and Drug Administration.

Source: State University of New Jersey

Explore further: FDA approves new drug for rare genetic disease

add to favorites email to friend print save as pdf

Related Stories

Gene therapy appears safe to regenerate gum tissue

Apr 07, 2009

Scientists at the University of Michigan have developed a method of gene delivery that appears safe for regenerating tooth-supporting gum tissue -- a discovery that assuages one of the biggest safety concerns surrounding ...

Go green for healthy teeth and gums

Mar 05, 2009

With origins dating back over 4,000 years, green tea has long been a popular beverage in Asian culture, and is increasingly gaining popularity in the United States. And while ancient Chinese and Japanese medicine believed ...

Recommended for you

Boxed warnings are common in novel therapeutics

20 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

22 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

22 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

tswogger
not rated yet Nov 01, 2007
hmm..I am wondering if the addition of a salicylic acid into this polymer is the best idea. Inflammation after trauma is the body's way of signaling the immune system to send a response to the site of trauma, as well as clotting components and the building blocks for tissue repair. By using aspirin in this polymer I would worry that healing time could actually be impared, but studies will reflect this if so.